CERTIFICATE

IMPACT FACTOR 2021

Subject Area

  • Life Sciences / Biology
  • Architecture / Building Management
  • Asian Studies
  • Business & Management
  • Chemistry
  • Computer Science
  • Economics & Finance
  • Engineering / Acoustics
  • Environmental Science
  • Agricultural Sciences
  • Pharmaceutical Sciences
  • General Sciences
  • Materials Science
  • Mathematics
  • Medicine
  • Nanotechnology & Nanoscience
  • Nonlinear Science
  • Chaos & Dynamical Systems
  • Physics
  • Social Sciences & Humanities

Why Us? >>

  • Open Access
  • Peer Reviewed
  • Rapid Publication
  • Life time hosting
  • Free promotion service
  • Free indexing service
  • More citations
  • Search engine friendly

A prospective study of efficacy and safety of conventional chemotherapy vs targeted therapy plus chemotherapy in recurrent and metastatic colorectal malignancies

Author: 
Amitabh Kumar Upadhyay, Pankaj Goyal, Prasanta Kumar Dash, Parveen Jain, Chaturbhuj Agrawal and Venkata Pradeep Babu Koyyala
Subject Area: 
Health Sciences
Abstract: 

Colorectal cancer (CRC) is an important health problem both globally and in India. It is the third most common malignant tumor and the fourth most common cause of cancer death in the World. In Indian population, there is paucity of literature on efficacy and toxicity profile of conventional vs targeted therapy plus chemotherapy in recurrent and metastatic colorectal malignancies. Present study was prospective study done to evaluate the Response rate and Progression free survival of conventional chemotherapy compared to that of Targeted therapy plus chemotherapy in first line setting in cases of recurrent or metastatic colorectal malignancies and also to assess the toxicity profile and overall survival on these drug combinations. Patients were enrolled from September 2013 to August 2014 and the date of last follow up was 20th June, 2015. Histologically or radiologically proven patients of recurrent and metastatic colorectal malignancies were enrolled for the study. A total of 70 patients were then enrolled into the study arm which received targeted therapy plus chemotherapy. 70 patients of similar demographic profile and disease status were randomly selected who received chemotherapy alone. The median PFS was 4 months and mean PFS was 5.51 months in the chemotherapy arm. The median PFS was 8 months and mean PFS was 7.21 months in the targeted therapy plus chemotherapy arm (p=0.001). The median OS was 19 months and mean OS was 18.03 months in the targeted therapy plus chemotherapy arm (p value <0.001). The overall response rate was 42.85% in chemotherapy arm and 62.85% in targeted therapy plus chemotherapy arm which was statistically significant. The rates of grade III and IV hematological adverse effects was comparable in both arms. There was 27.14% neutropenia, 12.85% thrombocytopenia, 14.28% anemia requiring transfusion and 14.28% cases of febrile neutropenia in chemotherapy arm. There was 30% neutropenia, 10% thrombocytopenia, 17.14% anemia requiring transfusion and 12.85% cases of febrile neutropenia in targeted therapy plus chemotherapy arm. The differences were not statistically significant.

PDF file: 

CALL FOR PAPERS

 

ONLINE PAYPAL PAYMENT

IJMCE RECOMMENDATION

Advantages of IJCR

  • Rapid Publishing
  • Professional publishing practices
  • Indexing in leading database
  • High level of citation
  • High Qualitiy reader base
  • High level author suport

Plagiarism Detection

IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.

 

EDITORIAL BOARD

CHUDE NKIRU PATRICIA
Nigeria
Dr. Swamy KRM
India
Dr. Abdul Hannan A.M.S
Saudi Arabia.
Luai Farhan Zghair
Iraq
Hasan Ali Abed Al-Zu’bi
Jordanian
Fredrick OJIJA
Tanzanian
Firuza M. Tursunkhodjaeva
Uzbekistan
Faraz Ahmed Farooqi
Saudi Arabia
Eric Randy Reyes Politud
Philippines
Elsadig Gasoom FadelAlla Elbashir
Sudan
Eapen, Asha Sarah
United State
Dr.Arun Kumar A
India
Dr. Zafar Iqbal
Pakistan
Dr. SHAHERA S.PATEL
India
Dr. Ruchika Khanna
India
Dr. Recep TAS
Turkey
Dr. Rasha Ali Eldeeb
Egypt
Dr. Pralhad Kanhaiyalal Rahangdale
India
DR. PATRICK D. CERNA
Philippines
Dr. Nicolas Padilla- Raygoza
Mexico
Dr. Mustafa Y. G. Younis
Libiya
Dr. Muhammad shoaib Ahmedani
Saudi Arabia
DR. MUHAMMAD ISMAIL MOHMAND
United State
DR. MAHESH SHIVAJI CHAVAN
India
DR. M. ARUNA
India
Dr. Lim Gee Nee
Malaysia
Dr. Jatinder Pal Singh Chawla
India
DR. IRAM BOKHARI
Pakistan
Dr. FARHAT NAZ RAHMAN
Pakistan
Dr. Devendra kumar Gupta
India
Dr. ASHWANI KUMAR DUBEY
India
Dr. Ali Seidi
Iran
Dr. Achmad Choerudin
Indonesia
Dr Ashok Kumar Verma
India
Thi Mong Diep NGUYEN
France
Dr. Muhammad Akram
Pakistan
Dr. Imran Azad
Oman
Dr. Meenakshi Malik
India
Aseel Hadi Hamzah
Iraq
Anam Bhatti
Malaysia
Md. Amir Hossain
Bangladesh
Ahmet İPEKÇİ
Turkey
Mirzadi Gohari
Iran